Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study - Takeaways - MDSpire

Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study

  • By

  • David Briskey

  • Janice Pellow

  • Pavitra Viswanath

  • Amanda Rao

  • July 15, 2026

Share

  • 1

    TRPTI™ is a bioavailable formulation of oleoylethanolamide (OEA) aimed at enhancing metabolic and appetite-related pathways.

  • 2

    In a crossover trial, 37 adults received either placebo or TRPTI™ doses of 150 mg or 300 mg, with blood samples collected over 8 hours.

  • 3

    The 300 mg TRPTI™ dose significantly increased GLP-1 and GIP levels compared to placebo, with effects detectable within 15 minutes.

  • 4

    Both TRPTI™ doses were well-tolerated, and safety biomarkers remained within normal ranges throughout the study.

  • 5

    A significant reduction in meal consumption was observed in both TRPTI™ groups, indicating potential effects on appetite.

Original Source(s)

Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study

  • by David Briskey, Janice Pellow, Pavitra Viswanath, Amanda Rao

  • July 15, 2026

Related Content

Efficacy of methimazole combined with traditional Chinese medicine in the treatment of Graves’ disease: a systematic review and network meta-analysis

The effect of type 2 diabetes on the prognosis of community-acquired pneumonia

Retraction Note: Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol